Compare J B Hunt Transport Services Inc (JBHT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs BIO-TECHNE Corp — how do they compare? J B Hunt Transport Services Inc trades at $290.9 (market cap $27.36B), while BIO-TECHNE Corp trades at $71.54 (market cap $11.16B). The key difference: J B Hunt Transport Services Inc is far larger — about 2.5× BIO-TECHNE Corp's market cap, and J B Hunt Transport Services Inc pays the higher dividend (0.62%). Which is the better fit depends on your goals.
| JBHT | TECH | |
|---|---|---|
Market Cap | $27.36B | $11.16B |
Sector | Industrials | Health |
52-Week High | $298.41 | $72.12 |
52-Week Low | $130.65 | $43.31 |
Enterprise Value | $28.50B | $11.24B |
Dividend Yield | 0.62% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $290.43, down 0.34% today but near its 52-week high, with a bullish technical outlook and consistent earnings beats. The stock shows strong momentum, supported by intermodal growth and cost discipline. Recent Q2 2026 EPS of $1.91 beat estimates by 12%, driving positive sentiment. Valuation remains elevated with a P/E of 41.45, reflecting high growth expectations amid industry capacity constraints.
Outlook is positive due to structural freight market shifts and operational efficiency, but risks include premium valuation sensitivity and economic cyclicality. Analyst consensus favors Buy with a $299.82 target, suggesting modest upside. Investors should weigh robust fundamentals against potential margin pressures from rising costs.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
